-+ 0.00%
-+ 0.00%
-+ 0.00%

TOP-REAL investigates whether digital monitoring can support earlier detection of toxicities and preserve continuity of one of the most effective treatments for HER2-positive metastatic breast cancer

Barchart·11/20/2026 06:21:00
Listen to the news

BARCELONA, Spain, Nov. 20, 2026 /PRNewswire/ -- Solti, an academic cancer clinical research group, has presented at the European ESMO AI & Digital Oncology 2026 congress the design of TOP-REAL, an international academic phase II study evaluating a proactive monitoring model for patients with advanced or metastatic HER2-positive breast cancer receiving first-line trastuzumab deruxtecan (T-DXd) plus pertuzumab.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.